Enhancement of the action of anti-infective agents and of central and peripheral nervous system agents and transportation of nucleic acid substances
원문보기
The invention provides a method of enhancing the action of a pharmaceutical agent selected from the group consisting of the anti-infective agents, the group comprising of the antimicrobial agents, the anthelmintic agents and the anti-ectoparasitic agents, but excluding coal tar solution and H1-antag
The invention provides a method of enhancing the action of a pharmaceutical agent selected from the group consisting of the anti-infective agents, the group comprising of the antimicrobial agents, the anthelmintic agents and the anti-ectoparasitic agents, but excluding coal tar solution and H1-antagonist antihistamines, and from the group consisting of the CPNS agents selected from the group of compounds acting on the central or peripheral nervous system, but excluding coal tar solution and H1-antagonist antihistamines and also excluding anti-inflammatory, analgesic and antipyretic agents and also provides an enhanced method for the administration of a nucleic acid substance to the cells of an animal, a plant or a micro-organism. The method is characterized in that the agent or nucleic acid substance is formulated with an administration medium which comprises a solution of nitrous oxide gas in a pharmaceutically acceptable carrier solvent for the gas and which administration medium includes at least one fatty acid or ester or other suitable derivative thereof selected from the group consisting of oleic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, arachidonic acid, eicosapentaenoic acid C20:5ω3, decosahexaenoic acid C22:6ω3, ricinoleic acid and derivatives thereof selected from the group consisting of the C1 to C6 alkyl esters thereof, the glycerol-polyethylene glycol esters thereof and the reaction product of hydrogenated natural oils composed largely of ricinoleic acid based oils, such as castor oil with ethylene oxide. The formulations of such agents or substances form part of the invention.
대표청구항▼
1. A method for the administration of a nucleic acid substance to cells of an animal, a plant or a micro-organism comprising administering to said animal, plant or microorganism, a composition comprising nucleic acid substance that is formulated with an administration medium which comprises an aqueo
1. A method for the administration of a nucleic acid substance to cells of an animal, a plant or a micro-organism comprising administering to said animal, plant or microorganism, a composition comprising nucleic acid substance that is formulated with an administration medium which comprises an aqueous solution of nitrous oxide gas in a physiologically acceptable carrier solvent for the gas and which the administration medium includes at least one fatty acid ethyl ester or glycerol-polyethylene glycol esters of ricinoleate, wherein said nucleic acid substance is selected from the group consisting of DNA, RNA, DNA-RNA hybrids, a gene or part thereof, a genome or part thereof, oligonucleotides and synthetic nucleic acids, andwherein the nitrous oxide is dissolved to saturation. 2. The method of claim 1, wherein the administration medium further comprises eicosapentaenoic acid [C20: 5ω3] and/or decosahexaenoic acid [C22: 6ω3], or ethyl esters thereof, as additional long chain fatty acids. 3. The method of claim 1, wherein the carrier solvent is water or a pharmaceutically acceptable alcohol, ether, polymer or an oil. 4. The method of claim 1, wherein the nucleic acid substance is formulated in a liquid formulation and wherein the formulation comprises, as part of the administration medium, water or acceptable other liquid solvent into which the nitrous oxide is dissolved and wherein the fatty acid ethyl ester is dissolved or suspended or emulsified along with the nucleic acid substance. 5. The method of claim 1, wherein the carrier solvent for the nitrous oxide gas is essentially non-aqueous and comprises the least one fatty acid ethyl ester. 6. The method of claim 5, wherein the nucleic acid substance is formulated to be suitable to be applied as a topical, buccal or vaginal cream or ointment, or skin patch or as an intravenous, intramuscular or subcutaneous injection, or as a suppository, or to be administered as an oral, nasal, or pulmonary preparation. 7. The method of claim 1, comprising formulating the nucleic acid substance to be applied as a topical, buccal or vaginal cream or ointment, or skin patch or as an intravenous, intramuscular or subcutaneous injection, or as a suppository, or to be administered as an oral, nasal, or pulmonary preparation, wherein the formulation used in formulating said cream, ointment, injectable formulation, suppository, or oral, nasal, or pulmonary preparation, incorporates, comprises the nucleic acid substance, a quantity of water containing nitrous oxide, a long chain fatty acid ethyl ester and, optionally further comprises adding excipients and additional carriers as are conventionally used in pharmaceutical trade to make dosage forms. 8. The method of claim 1, wherein the nucleic acid substance is selected from the group consisting of DNA, RNA, DNA-RNA hybrids, oligonucleotides and synthetic nucleic acids. 9. The method of claim 1, wherein the composition includes a peptide, peptide antibody or peptide derivative selective for a selected receptor or antigen or protein binding element on a target cell, the peptide being bound to at least one of the fatty acid ethyl ester in the composition. 10. The method of claim 3, wherein said water is deionized water. 11. The method of claim 3, wherein said oil is an organic oil. 12. The method of claim 11, wherein said organic oil is an essential oil based on long chain fatty acids having between 14 and 22 carbon atoms in the fatty acid. 13. The method of claim 12, wherein said essential oil is of natural origin. 14. The method of claim 13, wherein said essential oil of natural oil is a plant oil rich in gamma linolenic acid [GLA]. 15. The method of claim 8, wherein said nucleic acid substance is a DNA sequence coding for the expression of a chemokine, a chemotactin, a cytokine, an enzyme, a gonadotrophin, a growth factor, an immunoglobulin, an interferon, an interleukin, a lipid-binding protein, a pituitary hormone, a protease inhibitor, a protease, or a somatomedin. 16. The method of claim 1, wherein said administration medium comprises oleic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, arachidonic acid, eicosapentaenoic acid [C20: 5ω3], decosahexaenoic acid [C22: 6ω3], C1 to C6 alkyl esters of ricinoleic acid, or a reaction product of hydrogenated natural oils comprising ricinoleic acid based oils with ethylene oxide. 17. A composition for introducing a nucleic acid substance into cells of an animal, a plant or a micro-organism wherein the composition comprises a formulation of the nucleic acid in an administration medium which comprises an aqueous solution of nitrous oxide gas in a physiologically acceptable carrier solvent for the gas and which the administration medium includes at least one fatty acid ethyl ester or glycerol-polyethylene glycol esters of ricinoleate, wherein said nucleic acid substance is selected from the group consisting of DNA, RNA, DNA-RNA hybrids, a gene or part thereof, a genome or part thereof, oligonucleotides and synthetic nucleic acids, andwherein the nitrous oxide is dissolved to saturation. 18. A method for the administration of a nucleic acid substance to cells of an animal, a plant or a micro-organism comprising administering to said animal, plant or microorganism, a composition comprising nucleic acid substance that is formulated with an administration medium which comprises an aqueous solution of nitrous oxide gas in a physiologically acceptable carrier solvent for the gas and which the administration medium includes Vitamin F Ethyl Ester comprising fatty acid distribution: C18: 1.6%, wherein said nucleic acid substance is selected from the group consisting of DNA, RNA, DNA-RNA hybrids, a gene or part thereof, a genome or part thereof, oligonucleotides and synthetic nucleic acids, andwherein the nitrous oxide is dissolved to saturation.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (2)
Evan C. Unger, Acoustically active drug delivery systems.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.